These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32324651)

  • 1. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial.
    Matar M; Shamir R; Lev-Zion R; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Assa A
    J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):237-242. PubMed ID: 32324651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.
    Matar M; Shamir R; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Ben-Horin S; Assa A
    Inflamm Bowel Dis; 2020 Oct; 26(11):1627-1635. PubMed ID: 31793630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
    Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.
    Walters TD; Faubion WA; Griffiths AM; Baldassano RN; Escher J; Ruemmele FM; Hyams JS; Lazar A; Eichner S; Huang B; Li Y; Thakkar RB
    Inflamm Bowel Dis; 2017 Jun; 23(6):967-975. PubMed ID: 28301428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease].
    Navas-López VM; Pujol Muncunill G; Llerena E; Navalón Rubio M; Gil-Ortega D; Varea-Calderón V; Sierra Salinas C; Martin-de-Carpi J
    An Pediatr (Engl Ed); 2018 Feb; 88(2):89-99. PubMed ID: 28434894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients.
    Choi SY; Choi YO; Choe YH; Kang B
    J Korean Med Sci; 2020 Apr; 35(16):e114. PubMed ID: 32329259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.
    Pichler J; Huber WD; Aufricht C; Bidmon-Fliegenschnee B
    World J Gastroenterol; 2015 Jun; 21(21):6613-20. PubMed ID: 26074699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA; Dubinsky M; Ruemmele FM; Escher J; Rosh J; Hyams JS; Eichner S; Li Y; Reilly N; Thakkar RB; Robinson AM; Lazar A
    Inflamm Bowel Dis; 2017 Mar; 23(3):453-460. PubMed ID: 28129288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
    Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
    Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.